Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...
7don MSN
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback